New form of Taxol approved.

Share this article:

Bristol-Myers Squibb's Taxol and Sanofi-Aventis' Taxotere have new competition with a new FDA approval. The new drug, Abraxane –which is manufactured by American Pharmaceutical Partners, was approved for women with advanced breast cancer who have not responded to chemotherapy Abraxane features an easier administration and avoids some side effects.
In its clinical trial involving 460 women, tumors shrank in 21.5 percent of those who got Abraxane compared with 11.1 percent of those who received Taxol. The company has not yet provided data on whether Abraxane extended the lives of those women.
The women getting Abraxane in the trial had fewer cases of severe neutropenia, a decrease in white blood cells that can leave a patient vulnerable to infections. Some side effects like nerve damage, severe pain in the muscles or joints, and vomiting were more common with Abraxane.
American Pharmaceutical Partners, based in Schaumburg, Ill., is a generic maker that, with Abraxane, is moving into branded drugs.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.